Tripartite motif 10 regulates cardiac hypertrophy by targeting the PTEN/AKT pathway
Open Access
- 28 April 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (11), 6233-6241
- https://doi.org/10.1111/jcmm.15257
Abstract
The pathogenesis of cardiac hypertrophy is tightly associated with activation of intracellular hypertrophic signalling pathways, which leads to the synthesis of various proteins. Tripartite motif 10 (TRIM10) is an E3 ligase with important functions in protein quality control. However, its role in cardiac hypertrophy was unclear. In this study, neonatal rat cardiomyocytes (NRCMs) and TRIM10‐knockout mice were subjected to phenylephrine (PE) stimulation or transverse aortic constriction (TAC) to induce cardiac hypertrophy in vitro and in vivo, respectively. Trim10 expression was significantly increased in hypertrophied murine hearts and PE‐stimulated NRCMs. Knockdown of TRIM10 in NRCMs alleviated PE‐induced changes in the size of cardiomyocytes and hypertrophy gene expression, whereas TRIM10 overexpression aggravated these changes. These results were further verified in TRIM10‐knockout mice. Mechanistically, we found that TRIM10 knockout or knockdown decreased AKT phosphorylation. Furthermore, we found that TRIM10 knockout or knockdown increased ubiquitination of phosphatase and tensin homolog (PTEN), which negatively regulated AKT activation. The results of this study reveal the involvement of TRIM10 in pathological cardiac hypertrophy, which may occur by prompting of PTEN ubiquitination and subsequent activation of AKT signalling. Therefore, TRIM10 may be a promising target for treatment of cardiac hypertrophy.Keywords
Funding Information
- National Natural Science Foundation of China (81570207)
- Beijing Municipal Natural Science Foundation (7202004)
This publication has 26 references indexed in Scilit:
- Tripartite motif 32 prevents pathological cardiac hypertrophyClinical Science, 2016
- Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targetsArchives of Toxicology, 2015
- Quantification of Cardiomyocyte Hypertrophy by Cardiac Magnetic ResonanceCirculation, 2013
- Signaling effectors underlying pathologic growth and remodeling of the heartJCI Insight, 2013
- Cardiac Muscle Ring Finger-1 Increases Susceptibility to Heart Failure In VivoCirculation Research, 2009
- Downregulation of the Spi-1/PU.1 oncogene induces the expression of TRIM10/HERF1, a key factor required for terminal erythroid cell differentiation and survivalCell Research, 2008
- Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic TargetsPhysiology, 2007
- TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligasesBioEssays, 2005
- Cardiac Hypertrophy: The Good, the Bad, and the UglyAnnual Review of Physiology, 2003
- Left Ventricular HypertrophyCirculation, 2000